Skip to main content
RedHill Biopharma Ltd. logo

RedHill Biopharma Ltd. — Investor Relations & Filings

Ticker · RDHL ISIN · US7574681034 LEI · 52990034U7FZBKRAOE32 US Manufacturing
Open in API
Filings indexed 993 across all filing types
Latest filing 2018-03-26 Regulatory Filings
Country IL Israel
Listing US RDHL

About RedHill Biopharma Ltd.

https://www.redhillbio.com/

RedHill Biopharma is a specialty biopharmaceutical company focused on the development and commercialization of proprietary, orally-administered, small molecule drugs. The company's primary therapeutic areas of focus are gastrointestinal (GI) diseases, infectious diseases, and oncology. Its key commercial product is Talicia® for the treatment of Helicobacter pylori (H. pylori) infection. RedHill's late-stage clinical development pipeline includes several drug candidates. Among these are Opaganib, a broad-acting, host-directed antiviral and anti-inflammatory agent; RHB-204 for pulmonary nontuberculous mycobacteria (NTM) disease; and RHB-107 (upamostat), an oral serine protease inhibitor. A significant part of its strategy involves developing its assets for pandemic preparedness and as medical countermeasures, emphasizing therapies with viral mutation-resistant properties suitable for stockpiling.

Recent filings

Filing Released Lang Actions
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by a foreign private issuer, RedHill Biopharma Ltd., submitted to the SEC. It includes a press release about a scientific poster presentation on positive Phase II clinical trial results. The document is short (1966 characters) and primarily serves as a regulatory announcement of the press release rather than containing detailed financial data or comprehensive reports. Form 6-K filings are typically used for current reports by foreign private issuers and often fall under the category of Regulatory Filings (RNS) as they do not constitute full annual or interim reports, earnings releases, or other specific report types. Therefore, the appropriate classification is Regulatory Filings (RNS).
2018-03-26 English
FORM 6-K
AGM Information Classification · 95% confidence The document is a Form 6-K filed by RedHill Biopharma Ltd. It contains a detailed notice of the Annual General Meeting (AGM) including the date, agenda items such as appointment of auditors, share capital increase, board re-elections, option grants, and voting procedures. The document is not the AGM presentation or materials themselves but the official notice of the AGM. It is not an annual report, earnings release, or any other financial report. The content matches the definition of AGM Information (AGM-R) as it is the presentation and materials shared during the AGM, specifically the notice and agenda for the meeting. The document length (8580 characters) supports it being a full notice rather than a brief announcement. Therefore, the classification is AGM Information (AGM-R) with high confidence.
2018-03-21 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, RedHill Biopharma Ltd., with the SEC. It includes a press release about the company presenting at a conference. The document is short (1941 characters) and does not contain financial statements or detailed financial data. It is an announcement of an event (presentation at a conference) rather than a full report or detailed financial disclosure. Form 6-K filings typically serve as periodic reports for foreign private issuers to disclose material information. Given the content and length, this filing is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2018-03-20 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by a foreign private issuer, RedHill Biopharma Ltd., submitted to the SEC. It includes a press release about a poster presentation at a scientific meeting (AACR 2018 Annual Meeting). The document is short (1987 characters) and primarily serves as a regulatory announcement of an event or press release rather than containing detailed financial data or comprehensive reports. Form 6-K filings are typically used for current reports by foreign private issuers and often fall under the category of Regulatory Filings (RNS) when they do not contain full financial statements or detailed reports. Therefore, this document is best classified as a Regulatory Filing (RNS).
2018-03-19 English
20-F
Annual Report FY 2017
2018-02-22 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, RedHill Biopharma Ltd., with the SEC. It includes a press release titled 'RedHill Biopharma Provides Fourth Quarter and Full-Year 2017 Investor Update.' Form 6-K filings are typically used by foreign private issuers to report material information that is not required to be filed on Forms 20-F or 40-F. The document is short (1936 characters) and primarily serves as an announcement of the press release rather than containing detailed financial statements or comprehensive analysis. Therefore, it does not qualify as an Annual Report (10-K), Interim Report (IR), or Earnings Release (ER). Given the nature and length, this filing fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2018-02-22 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.